Oxygen Bio Dismisses CEO Chris Stern and Appoints CFO Michael Jebsen as Interim CEO
Oxygen Biotherapeutics has dismissed Chris Stern as chief executive officer (CEO) and chairman and has named Michael Jebsen as interim CEO. Jebsen will retain his positions as chief financial officer (CFO) and treasurer.
Jebsen has served as Oxygen’s CFO, secretary and treasurer since August 2009 and has a thorough understanding of Oxygen’s day-to-day business operations, overall strategic plan and financial situation. He first joined Oxygen as its accounting manager in April 2009, and was elected CFO, executive vice president (EVP) finance and administration, corporate secretary and treasurer in August 2009. Before joining Oxygen, he was an auditor with Grant Thornton, LLP from July 2003 through December 2005 and from April 2008 through April 2009.
In addition, Jebsen held various positions, including chief ethics officer, senior internal auditor and senior financial analyst with RTI International, a non-profit research and development organisation, from January 2006 to February 2008. He holds an MSc in Accounting from East Carolina University and is a certified public accountant (CPA), licensed in North Carolina.